about
Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screeningMicrofluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience[Backstage of a massive open online course (MOOC) on cancer diagnosis].Automated microdroplet platform for sample manipulation and polymerase chain reaction.Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsInhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewIn vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options.Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.Controversies concerning the use of phytoestrogens in menopause management: bioavailability and metabolism.Prognostic factors for local recurrence following breast-conserving treatment in young women.Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes.A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk.Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.p53 in breast cancer subtypes and new insights into response to chemotherapy.Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients.Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma.A new model of patient tumor-derived breast cancer xenografts for preclinical assays.Role of chemotherapy resistance genes in outcome of neuroblastoma.Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
P50
Q24684588-7BBDC2C0-E784-4E98-A447-972618737D21Q27316870-D24A6F45-C77C-44C6-A570-1C7049961F5DQ28534874-D40F375C-BF81-433E-B78E-D69A56F4EF0CQ30489855-9D2437B3-E988-46EC-9AC4-D567FFDC26A7Q33263555-DEEA77DA-3A2F-483A-B558-DCD3AB8593B0Q33304051-95668EEF-510E-4B86-A5E3-F80346768523Q33739841-DA3D0A8F-2A0B-44E2-B7D8-FC8C7D62A1ACQ33919243-591E64FE-6456-44A7-80DA-236FA62C4398Q34301953-9DCA1FF1-82E9-4FD8-A39D-064E12293641Q34855870-D59700F8-E02E-4B9B-9B8F-F7BF1D28C114Q35794363-650D47D9-B342-4F12-92C2-5E1E3DAB3C25Q35904441-E60EBC3D-0FBB-4571-A6AF-4503A67173DCQ35925289-B025FF34-F138-4BBC-B0B0-B28CA69B1C67Q36459973-F4898406-81F8-46D4-9778-1383332BB062Q37238756-BD03E0EA-0979-470C-BC6D-AE5FED0C6296Q37360208-8729DC36-CA48-463E-96C6-2D1EE9D240C2Q37566580-BF8EC2CD-48D2-4402-B825-31ADA955CE70Q37676654-557B8113-6DD6-498D-A474-957976BABE5FQ37782089-11720A44-E18D-453C-B077-A29B93790007Q37809195-F1A84835-C064-402D-BF78-958EB2B38916Q37911040-6EC39898-B236-40DF-93CE-9A595EE36B90Q38104997-85341FE7-69CF-4A7C-8C0A-341028C01464Q38145813-58A0DEBF-CA20-41CC-93EF-C184DB9BBA97Q38443820-6E3CEE7A-5C9D-4C6E-850F-BC8C199E40C7Q38655004-3B4327AE-FBFE-4350-B395-8FC88BDFDADFQ39676823-23C3B951-3E0A-4840-A1B5-D9A5D36D072FQ39696315-026E7690-9C97-4AD7-9C76-5B9264EB2D66Q40112517-74D2455A-BECB-4125-9D52-F3CF3E66C2B2Q40293489-CB0B78BF-A3C9-43F9-9C8B-B15744CFF5B3Q40492056-63725CA1-DA12-46C2-9C0D-B4E03AE1E5B7
P50
description
onderzoeker
@nl
name
Patricia de Cremoux
@ast
Patricia de Cremoux
@en
Patricia de Cremoux
@es
Patricia de Cremoux
@sl
type
label
Patricia de Cremoux
@ast
Patricia de Cremoux
@en
Patricia de Cremoux
@es
Patricia de Cremoux
@sl
prefLabel
Patricia de Cremoux
@ast
Patricia de Cremoux
@en
Patricia de Cremoux
@es
Patricia de Cremoux
@sl